|Videos|September 11, 2020

Reducing Readmissions Due to Heart Failure

Episodes in this series

EP. 1 Pathophysiology of Different Types of Heart Failure

EP. 2 Progressive Nature and Associated Risks of Diabetes on HF

EP. 3 Cost and Utilization Profile for a Patient With HF

EP. 4 Economic Burden of Heart Failure and Goals of Treatment

EP. 5 Standard of Care in Patients With Heart Failure

Now Playing

EP. 6 Reducing Readmissions Due to Heart Failure

EP. 7 CV Outcomes Studies With Medications Indicated for Diabetes

EP. 8 Recent Studies of SGLT-2s in Patients with HFrEF

EP. 9 Implications of Using SGLT2 Inhibitors With HFpEF and HFrEF

EP. 10 SGLT2 Inhibitors in Patients Without Diabetes at Risk of HF

EP. 11 SGLT2 Inhibitors as Standard of Care Throughout Cardiology

EP. 12 Guidelines Regarding Use of SGLT2s for Patients With Diabetes and HF

EP. 13 Quantifying Potential Impact of SGLT2 Inhibitors for HF

EP. 14 Systemic Change to Support Care of Patients With HF

EP. 15 Treatment of Patients With Heart Failure

EP. 16 Interest Regarding Diabetes and CVD Risk

EP. 17 Takeaways of DAPA-HF: SGLT2s for CVD

EP. 18 Using SGLT2 Inhibitors to Achieve Cardiovascular Benefits

EP. 19 Cost-Effectiveness of SGLT2s for CVD

Nihar Desai, MD, MPH, and Jaime Murillo, MD, discuss the quality measures used and efforts undertaken to reduce rehospitalization due to heart failure.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Older man with laptop in front of him taking telehealth appointment. | Image Credit: fizkes-stock.adobe.com.jpeg

Nurse-Delivered Telehealth Falls Short for Diabetes in Fee-for-Service Trial

ByElla Hohmann, MS

June 23rd 2026

Resistance band exercise | Image credit: Alex & M Studio - stock.adobe.com

Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk

ByPearl Steinzor

June 22nd 2026

Diabetes monitoring | Image credit: abidika - stock.adobe.com

Telemedicine Diabetes Clinic Cuts HbA1c in Incarcerated Men

ByPearl Steinzor

June 17th 2026

Evolocumab Cuts MACE by 29% in High-Risk Diabetes Without Prior MI or Stroke: Lawrence Leiter, MD

ByGiuliana Grossi,Lawrence Leiter, MD

June 15th 2026

American Diabetes Association Scientific Sessions 2026 Recap

ADA 2026: Triple Hormonal Therapy, Cardiovascular Breakthroughs, and the Push for Equitable Care

ByGiuliana Grossi

June 12th 2026

Reducing Readmissions Due to Heart Failure

Episodes in this series

EP. 1 Pathophysiology of Different Types of Heart Failure

EP. 2 Progressive Nature and Associated Risks of Diabetes on HF

EP. 3 Cost and Utilization Profile for a Patient With HF

EP. 4 Economic Burden of Heart Failure and Goals of Treatment

EP. 5 Standard of Care in Patients With Heart Failure

EP. 6 Reducing Readmissions Due to Heart Failure

EP. 7 CV Outcomes Studies With Medications Indicated for Diabetes

EP. 8 Recent Studies of SGLT-2s in Patients with HFrEF

EP. 9 Implications of Using SGLT2 Inhibitors With HFpEF and HFrEF

EP. 10 SGLT2 Inhibitors in Patients Without Diabetes at Risk of HF

EP. 11 SGLT2 Inhibitors as Standard of Care Throughout Cardiology

EP. 12 Guidelines Regarding Use of SGLT2s for Patients With Diabetes and HF

EP. 13 Quantifying Potential Impact of SGLT2 Inhibitors for HF

EP. 14 Systemic Change to Support Care of Patients With HF

EP. 15 Treatment of Patients With Heart Failure

EP. 16 Interest Regarding Diabetes and CVD Risk

EP. 17 Takeaways of DAPA-HF: SGLT2s for CVD

EP. 18 Using SGLT2 Inhibitors to Achieve Cardiovascular Benefits

EP. 19 Cost-Effectiveness of SGLT2s for CVD

Related Content

Nurse-Delivered Telehealth Falls Short for Diabetes in Fee-for-Service Trial

Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk

Telemedicine Diabetes Clinic Cuts HbA1c in Incarcerated Men

Evolocumab Cuts MACE by 29% in High-Risk Diabetes Without Prior MI or Stroke: Lawrence Leiter, MD

ADA 2026: Triple Hormonal Therapy, Cardiovascular Breakthroughs, and the Push for Equitable Care

Trending on AJMC

ATTR-CM Incidence, Prevalence Rose Sharply in the US

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Natera's Moshkevich Discusses TOMR Approach and the Future of MRD-Guided Care

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Reducing Readmissions Due to Heart Failure

Episodes in this series

EP. 1 Pathophysiology of Different Types of Heart Failure

EP. 2 Progressive Nature and Associated Risks of Diabetes on HF

EP. 3 Cost and Utilization Profile for a Patient With HF

EP. 4 Economic Burden of Heart Failure and Goals of Treatment

EP. 5 Standard of Care in Patients With Heart Failure

EP. 6 Reducing Readmissions Due to Heart Failure

EP. 7 CV Outcomes Studies With Medications Indicated for Diabetes

EP. 8 Recent Studies of SGLT-2s in Patients with HFrEF

EP. 9 Implications of Using SGLT2 Inhibitors With HFpEF and HFrEF

EP. 10 SGLT2 Inhibitors in Patients Without Diabetes at Risk of HF

EP. 11 SGLT2 Inhibitors as Standard of Care Throughout Cardiology

EP. 12 Guidelines Regarding Use of SGLT2s for Patients With Diabetes and HF

EP. 13 Quantifying Potential Impact of SGLT2 Inhibitors for HF

EP. 14 Systemic Change to Support Care of Patients With HF

EP. 15 Treatment of Patients With Heart Failure

EP. 16 Interest Regarding Diabetes and CVD Risk

EP. 17 Takeaways of DAPA-HF: SGLT2s for CVD

EP. 18 Using SGLT2 Inhibitors to Achieve Cardiovascular Benefits

EP. 19 Cost-Effectiveness of SGLT2s for CVD

Related Content

Nurse-Delivered Telehealth Falls Short for Diabetes in Fee-for-Service Trial

Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk

Telemedicine Diabetes Clinic Cuts HbA1c in Incarcerated Men

Evolocumab Cuts MACE by 29% in High-Risk Diabetes Without Prior MI or Stroke: Lawrence Leiter, MD

ADA 2026: Triple Hormonal Therapy, Cardiovascular Breakthroughs, and the Push for Equitable Care

Trending on AJMC

ATTR-CM Incidence, Prevalence Rose Sharply in the US

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Natera's Moshkevich Discusses TOMR Approach and the Future of MRD-Guided Care